Method for treating hematopoietic neoplasms
AssigneeOXiGENE, Inc.
InventorsDavid Chaplin, Bronwyn G. Siim
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.
Claims11
A method of treating a myeloid neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound is combretastatin A-1 diphosphate (CA1dP):
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.